参考文献/References:
[1]Aribi Al-Zoobaee FW,Yee Shen L,Veettil SK,et al.Antiviral Agents for the Prevention and Treatment of Herpes Simplex Virus Type-1 Infection in Clinical Oncology: A Network Meta-Analysis[J].Int J Environ Res Public Health,2020,17(23):8891.[2]Ford ES,Sholukh AM,Boytz R,et al.B cells, antibody-secreting cells, and virus-specific antibodies respond to herpes simplex virus 2 reactivation in skin[J].J Clin Invest,2021,131(9):e142088.[3]Luyt CE,Forel JM,Hajage D,et al.Acyclovir for Mechanically Ventilated Patients With Herpes Simplex Virus Oropharyngeal Reactivation: A Randomized Clinical Trial[J].JAMA Intern Med,2020,180(2):263-272.[4]Breier A,Buchanan RW,D’Souza D,et al.Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study[J].Schizophr Res,2019,206:291-299.[5]Chesney J,Puzanov I,Collichio F,et al.Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of TalimogeneLaherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma[J].J Clin Oncol,2018,36(17):1658-1667.[6]Kelly CM,Antonescu CR,Bowler T,et al.Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With TalimogeneLaherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial[J].JAMA Oncol,2020,6(3):402-408.[7]Nomura T,Sumi E,Egawa G,et al.The efficacy of a cyclin dependent kinase 9 (CDK9) inhibitor, FIT039, on verruca vulgaris: study protocol for a randomized controlled trial[J].Trials,2019,20(1):489.[8]Scepanovic P,Alanio C,Hammer C,et al.Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines[J].Genome Med,2018,10(1):59.[9]Armour M,Semprini A,Ee C,et al.Efficacy of a topical herbal and mineral formulation (Dynamiclear) for the treatment of herpes simplex labialis in the community setting: study protocol for a randomised, double-blind placebo-controlled trial[J].BMJ Open,2020,10(1):e031876.[10]Andtbacka RHI,Amatruda T,Nemunaitis J,et al.Biodistribution, shedding, and transmissibility of the oncolytic virus talimogenelaherparepvec in patients with melanoma[J].EBio Medicine,2019,47:89-97.[11]Li C,Li Y,Yang Y,et al.The Detection and Characterization of Herpes Simplex Virus Type 1 in Confirmed Measles Cases[J].Sci Rep,2019,9(1):12785.[12]Dropulic LK,Oestreich MC,Pietz HL,et al.A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection[J].J Infect Dis,2019,220(6):990-1000.[13]Nelson CS,Huffman T,Jenks JA,et al.HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions[J].Proc Natl Acad Sci U S A,2018,115(24):6267-6272.[14]Streby KA,Currier MA,Triplet M,et al.First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial[J].Mol Ther,2019,27(11):1930-1938.[15]Piret J,Boivin G.Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis[J].Clin Microbiol Rev,2020,33(2):e00105-e00119.
相似文献/References:
[1]展帮乐,阮建波,朱和玲,等.生殖器疱疹高危人群两种血清学检测方法阳性率的比较[J].医学信息,2019,32(17):178.[doi:10.3969/j.issn.1006-1959.2019.17.061]
ZHAN Bang-le,RUAN Jian-bo,ZHU He-ling,et al.Comparison of Positive Rates of Two Serological Tests for High Risk Population of Genital Herpes[J].Journal of Medical Information,2019,32(21):178.[doi:10.3969/j.issn.1006-1959.2019.17.061]
[2]马美刚,吴 原.抗NMDA受体脑炎的临床特点和脑电图表现[J].医学信息,2020,33(12):20.[doi:10.3969/j.issn.1006-1959.2020.12.008]
MA Mei-gang,WU Yuan.Clinical Characteristics and Electroencephalogram of Anti-NMDA Receptor Encephalitis[J].Journal of Medical Information,2020,33(21):20.[doi:10.3969/j.issn.1006-1959.2020.12.008]